Lastly, a retrospective study on 250 patients of mixed tumor types treated with anti-PD-1 or anti-PD-L1 determined that obesity improved both PFS (237 days vs 141 days, HR= 0.61 [95% CI, 0.42-0.89] and OS (523 days versus 361 days, HR of 0.59 [95% CI, 0.35-0.99]) after controlling for ECOG performance status, line of therapy, age, biological sex, and cancer type (25) (Table 1). This evidence concerns the gene PDCD1 and obesity due to melanocortin 4 receptor deficiency.